Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
A phase 1/2 trial of TNG462, Zoldonrasib, Daraxonrasib in pancreatic ductal adenocarcinoma, run by Tango Therapeutics, Inc., now recruiting.
Overview
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients is a phase 1/2 interventional study registered as NCT06922591 by Tango Therapeutics, Inc., with 183 participants planned, started 2025-05-31 and due to reach its primary completion in 2027-06. Interventions recorded: TNG462, RMC-9805, RMC-6236, mFOLFIRINOX, gemcitabine/nab-paclitaxel. Conditions listed: PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut
Shares Zoldonrasib, Daraxonrasib, Gemcitabine, Paclitaxel / nab-paclitaxel.
- TrialStudy of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Shares Zoldonrasib, Daraxonrasib, Gemcitabine, Paclitaxel / nab-paclitaxel.
- TrialA Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have N
Shares FOLFIRINOX / mFOLFIRINOX, Gemcitabine, Paclitaxel / nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- IdeaRAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable
Shares FOLFIRINOX / mFOLFIRINOX, Zoldonrasib, Daraxonrasib, Pancreatic ductal adenocarcinoma.
- TrialStudy of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Shares Daraxonrasib, Gemcitabine, Paclitaxel / nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- TrialS095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Shares TNG462, Tango Therapeutics.
- PairingG12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib)
Shares Zoldonrasib, Daraxonrasib, Pancreatic ductal adenocarcinoma.
- TrialSafety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Shares TNG462, Tango Therapeutics.